Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.19) per share which beat the anal

Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 millio

-- Reaffirms 2026 Guidance -- -- Multiple New Business Wins, Adding Impactful Programs to Pipeline -

CHASKA, Minn., July 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecor

--Technology Transfer Agreement for Regenerative Medicine Late-Stage Development Program-- --Two Add

CHASKA, Minn. , July 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecor

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Ou

--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Prod

-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Inject

-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Inject

CHASKA, Minn. , May 21, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore

CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:  LFCR ) (“Lifecor

Lifecore Biomedical, Inc. (LFCR) Q1 2026 Earnings Call Transcript

Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 millio

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.43) per share which missed the an

-- Reaffirms 2026 Guidance -- -- Signed Three New Commercial Site Transfer Programs in First Quarter

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Ou

CHASKA, Minn., April 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:  LFCR ) (“Lifec

CHASKA, Minn., April 22, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecor

Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR - Get Free Report) have received a consensus recom

CHASKA, Minn., April 08, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecor

SAINT PAUL, Minn., April 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP and The Rosen Law Firm, P.A. ann

Kezar Life Sciences (NASDAQ: KZR - Get Free Report) and Lifecore Biomedical (NASDAQ: LFCR - Get Free

CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecor

Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contrac

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.16) per share. This is a 20 perce

Barrington Research analyst Michael Petusky upgrades Lifecore Biomedical (NASDAQ:LFCR) from Marke

Lifecore stock plunges after earnings miss and weak 2026 outlook, with customer losses and delayed g

Lifecore Biomedical (NASDAQ:LFCR) sees FY2026 sales of $120.000 million-$125.000 million vs $129.846

Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered wi

Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract developmen

Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $74.000 million-$76.000 million

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.29) per share which beat the anal

Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract developmen

Keybanc analyst Paul Knight initiates coverage on Lifecore Biomedical (NASDAQ:LFCR) with a Sector

Lifecore Biomedical (NASDAQ:LFCR) sees FY2026 sales of $74.000 million-$76.000 million vs $127.802 m

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.06) per share which beat the anal

Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract developmen

William Blair analyst Max Smock initiates coverage on Lifecore Biomedical (NASDAQ:LFCR) with a Ou

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.47) per share which missed the an